Immuneering (NASDAQ:IMRX) Receives Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note published on Thursday,Benzinga reports. Chardan Capital currently has a $20.00 price objective on the stock.

Other research analysts also recently issued reports about the company. Leerink Partners began coverage on Immuneering in a report on Friday, October 31st. They set an “outperform” rating and a $15.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research report on Tuesday, September 30th. Needham & Company LLC upped their target price on Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, September 15th. Leerink Partnrs upgraded shares of Immuneering to a “strong-buy” rating in a research report on Friday, October 31st. Finally, Mizuho set a $12.00 price objective on shares of Immuneering in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Immuneering currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Trading Down 1.6%

IMRX traded down $0.10 during trading on Thursday, reaching $6.35. 1,301,302 shares of the company’s stock were exchanged, compared to its average volume of 1,270,564. Immuneering has a one year low of $1.10 and a one year high of $10.08. The firm has a fifty day moving average price of $6.86 and a two-hundred day moving average price of $4.39. The stock has a market capitalization of $263.97 million, a PE ratio of -3.57 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Sell-side analysts expect that Immuneering will post -1.86 earnings per share for the current year.

Insider Transactions at Immuneering

In other news, Director Peter Feinberg acquired 7,500 shares of Immuneering stock in a transaction on Friday, October 3rd. The stock was purchased at an average price of $6.67 per share, with a total value of $50,025.00. Following the completion of the purchase, the director owned 156,766 shares of the company’s stock, valued at approximately $1,045,629.22. The trade was a 5.02% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 20,800 shares of company stock valued at $143,754 in the last 90 days. 22.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immuneering

Large investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in Immuneering in the 3rd quarter valued at $98,000. Southport Management L.L.C. lifted its stake in shares of Immuneering by 11.2% in the third quarter. Southport Management L.L.C. now owns 272,501 shares of the company’s stock valued at $1,908,000 after buying an additional 27,501 shares in the last quarter. Burkehill Global Management LP bought a new position in shares of Immuneering in the third quarter valued at $2,100,000. Two Sigma Investments LP grew its holdings in shares of Immuneering by 481.4% during the third quarter. Two Sigma Investments LP now owns 107,871 shares of the company’s stock valued at $755,000 after buying an additional 89,318 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in shares of Immuneering by 26.2% during the third quarter. Bridgeway Capital Management LLC now owns 120,449 shares of the company’s stock worth $843,000 after acquiring an additional 25,000 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.